|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Cash flows from operating activities | ||
| Net income (loss) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Changes in operating assets and liabilities: | ||
| Deferred offering cost | ||
| Accounts payable | ||
| Prepaid expenses | ||
| Tax liability | ||
| Interest expense | ||
| Net cash used in operating activities | ||
| Cash flows from investing activities | ||
| Investment in trust account | ||
| Net cash used in investing activities | ||
| Cash flows from financing activities | ||
| Proceeds from promissory note | ||
| Repayment of promissory note | ||
| Proceeds from sale of 8,000,000 units at $10 per unit in IPO net of offering cost paid at closing | ||
| Proceeds from sale of 248,300 units to Sponsor in private placement | ||
| Proceeds from sale of 40,000 units to underwriters in private placement | ||
| Proceeds from sale of 1,000,000 $15 strike warrants in private placement | ||
| Net cash provided by Financing activities | ||
| Net increase in cash | ||
| Cash at beginning of period | ||
| Cash at end of period | ||
| Supplemental disclosure for non-cash financing activities: | ||
| Accrual of offering costs | ||
| Offering cost |
Loading...
